PLEASANTON, CA -- (MARKET WIRE) -- March 08, 2007 -- CARDIOVASCULAR REVASCULARIZATION THERAPIES (CRT) 2007 SYMPOSIUM -- Lipid Sciences, Inc. (NASDAQ: LIPD) announced today that new data presented at Cardiovascular Revascularization Therapies: CRT 2007 Symposium highlighted the scientific basis of Lipid Sciences' proprietary HDL Selective Delipidation process that is currently being evaluated in a clinical trial setting at the Washington Hospital Center (WHC).
